List of Excipients in Branded Drug WAL-ITIN D

« Back to Dashboard

Generic Drugs Containing WAL-ITIN D

Company	Ingredient	NDC	Excipient
Walgreens	loratadine and pseudoephedrine sulfate	0363-2390	CANDELILLA WAX
Walgreens	loratadine and pseudoephedrine sulfate	0363-2390	FERROSOFERRIC OXIDE
Walgreens	loratadine and pseudoephedrine sulfate	0363-2390	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in WAL-ITIN D?

# Of NDCs	Excipient
1	CANDELILLA WAX
1	FERROSOFERRIC OXIDE
1	GLYCERYL MONOSTEARATE

WAL-ITIN D Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

WAL-ITIN D is a private-label extended-release allergy product containing loratadine and pseudoephedrine sulfate, generally positioned as an alternative to Claritin-D 24 Hour. Its commercial value depends less on active-ingredient exclusivity than on reliable extended-release performance, low-cost excipient sourcing, regulatory compliance, and retail-channel execution. The strongest opportunities are formulation simplification, dye-free and lactose-free variants, abuse-deterrent packaging, and supply-chain differentiation.

What is WAL-ITIN D and which dosage form does it use?

WAL-ITIN D is marketed as an oral extended-release tablet for temporary relief of allergy and nasal-congestion symptoms. The standard 24-hour strength contains:

Component	Typical amount per tablet	Function
Loratadine	10 mg	Antihistamine
Pseudoephedrine sulfate	240 mg	Nasal decongestant
Dosage form	Extended-release tablet	Maintains pseudoephedrine exposure over approximately 24 hours

The product is generally comparable in active ingredients and intended use to Claritin-D 24 Hour. The precise inactive-ingredient profile can vary by manufacturer, manufacturing site, and product presentation. The current package label and DailyMed entry should control any formulation or regulatory assessment.[1]

The formulation presents a technical challenge because loratadine is used at a low dose while pseudoephedrine sulfate represents most of the tablet mass. The excipient system must provide content uniformity for loratadine, control pseudoephedrine release, preserve tablet integrity, and support high-speed manufacturing.

What excipients are likely to be used in WAL-ITIN D?

A typical formulation would use a combination of fillers, binders, disintegrants, lubricants, glidants, release-controlling polymers, and coating materials. Public labels for equivalent loratadine/pseudoephedrine products commonly identify excipients such as microcrystalline cellulose, lactose or another diluent, povidone, croscarmellose sodium, sodium starch glycolate, magnesium stearate, silicon dioxide, talc, and film-coating components.[1][2]

The exact formulation should not be inferred solely from the active ingredients. Products with the same strength can use materially different excipient systems and still satisfy the applicable regulatory requirements.

Functional role of the core excipients

Excipient category	Common candidates	Commercial and technical role
Diluent	Microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Provides tablet mass and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Supports immediate breakup of non-release portions
Lubricant	Magnesium stearate, sodium stearyl fumarate	Prevents sticking and improves ejection
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Release modifier	Hypromellose, ethylcellulose, methacrylate polymers	Controls pseudoephedrine release
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides, talc	Protects the tablet and supports product identification

The primary formulation risk is over-lubrication. Excess magnesium stearate can reduce wettability and slow dissolution, which may shift the release profile of pseudoephedrine. Moisture exposure can also affect flow, compression, coating adhesion, and long-term dissolution.

What excipient strategy best supports a commercial WAL-ITIN D product?

The most practical strategy is a robust hydrophilic matrix or multipart-stage release design that uses widely available compendial excipients and avoids unnecessary dependence on proprietary polymers.

1. Use a high-throughput, low-variance tablet process

A direct-compression process can reduce manufacturing steps, but loratadine content uniformity may be difficult because the dose is small relative to the pseudoephedrine load. A dry-granulation or roller-compaction process can improve flow and segregation control while avoiding the thermal and moisture exposure associated with wet granulation.

A commercial process should prioritize:

• Narrow particle-size distributions for both active ingredients.
• Controlled bulk density and flow.
• Separate premixing or ordered blending for low-dose loratadine.
• Low-shear final blending to limit segregation.
• Defined lubrication time to protect dissolution performance.
• In-process controls for weight, hardness, thickness, friability, and assay uniformity.

The preferred process depends on the selected excipient grades and the manufacturing equipment available at the contract manufacturer.

2. Select the release-control polymer around dissolution performance

Pseudoephedrine sulfate is highly water-soluble. A formulation that relies only on tablet hardness may show excessive early release or batch-to-batch variability. A hydrophilic polymer matrix, commonly based on hypromellose, can provide a more predictable release curve.

The polymer system should be selected against:

• Dissolution in multiple pH media.
• Agitation sensitivity.
• Tablet dimensions and compression force.
• Food-effect performance.
• Alcohol-induced release acceleration.
• Stability under high humidity.
• Compatibility with film coating.

The commercial target is not simply a slower release. It is reproducible release that matches the reference product or the applicable regulatory benchmark.

3. Reduce excipient complexity

A lower-excipient-count formulation can improve procurement, quality control, and manufacturing economics. However, removing an excipient is commercially useful only if it does not increase dissolution variability, tablet defects, or stability risk.

Potential simplification routes include:

• Combining filler and binder functionality with a multifunctional microcrystalline cellulose grade.
• Replacing separate glidant and lubricant optimization with a validated co-processed excipient.
• Using a single polymeric release modifier instead of multiple viscosity grades.
• Eliminating unnecessary colorants for a dye-free presentation.
• Replacing lactose where a lactose-free or reduced-allergen claim has retail value.

Excipients should remain compendial where possible. A novel excipient would add regulatory burden and offer limited value for a mature OTC product.

What formulation improvements create commercial opportunities?

The most credible opportunities are incremental rather than radical.

Dye-free and lactose-free variants

A dye-free tablet can address consumer preferences and simplify colorant-related labeling. A lactose-free formulation can broaden use among consumers who avoid lactose, although lactose in a solid oral product is not equivalent to a meaningful lactose exposure in most consumers.

These variants can be developed by replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. The replacement must be evaluated for:

• Tablet hardness.
• Compression force.
• Moisture uptake.
• Pseudoephedrine dissolution.
• Loratadine assay uniformity.
• Coating appearance.
• Stability under accelerated and long-term conditions.

A dye-free version may have stronger retail value than a lactose-free claim because it is easier for consumers to understand and can be implemented without changing the active-ingredient profile.

Smaller tablets and improved swallowability

A 240 mg pseudoephedrine sulfate load creates a large tablet. Tablet size can be reduced through higher-density excipients, more efficient compression, or a bilayer or multiparticulate architecture. Size reduction must not compromise matrix integrity or produce dose dumping.

Commercially viable approaches include:

• High-density calcium phosphate or co-processed filler systems.
• Roller compaction to improve bulk density.
• Film coating rather than sugar coating.
• Optimized tooling and tablet shape.
• Multiparticulate granules compressed into a smaller tablet.

A smaller tablet could support a premium private-label tier, but the cost increase must be measured against retail price sensitivity.

Tamper-resistant packaging

Pseudoephedrine is subject to federal and state controls because it can be diverted for illicit methamphetamine production. The Combat Methamphetamine Epidemic Act imposes sales, storage, identification, and purchase-record requirements for scheduled-list chemical products, including pseudoephedrine-containing products.[3]

Packaging opportunities include:

• Unit-dose blister packs.
• Limited-count cartons.
• Anti-counterfeit serialization.
• Transparent purchase-limit messaging.
• Packaging that reduces tablet removal without authorization.

Packaging cannot eliminate the statutory requirements for behind-the-counter sale, identification, and transaction records. It can reduce diversion, improve inventory control, and support retailer compliance.

Abuse-resistant formulation claims

An abuse-deterrent claim would be difficult to justify for a standard loratadine/pseudoephedrine tablet and could add substantial development and regulatory complexity. A better near-term strategy is abuse-resistant packaging and controlled retail handling rather than a new abuse-deterrent dosage form.

What regulatory pathway applies to WAL-ITIN D?

WAL-ITIN D is an OTC product rather than a conventional prescription drug. Loratadine and pseudoephedrine have established OTC regulatory histories, and the product is generally marketed under applicable FDA OTC conditions or through an approved reference-product pathway, depending on the specific product and manufacturer.[4]

The regulatory assessment should address:

• Active-ingredient identity and strength.
• Extended-release performance.
• Required allergy and decongestant labeling.
• Age restrictions and warnings.
• Pseudoephedrine sales controls.
• Stability and container-closure performance.
• Manufacturing under current good manufacturing practice requirements.
• Labeling consistency between the carton, bottle, blister, and Drug Facts panel.

Because pseudoephedrine is regulated as a listed chemical, a product can be FDA-compliant yet still face operational restrictions at the point of sale.

What is the Orange Book status of WAL-ITIN D?

WAL-ITIN D itself is not ordinarily evaluated as a standalone Orange Book innovator product. Private-label OTC products generally do not receive the same patent-listing profile as a prescription NDA product. The Orange Book is principally relevant to approved prescription drugs and certain approved OTC products that use an NDA framework.[5]

Accordingly:

• A conventional Orange Book patent listing should not be assumed for the Walgreens private-label product.
• A Paragraph IV certification is generally not the primary challenge mechanism for an OTC monograph product.
• Generic competition can enter through OTC monograph compliance, an abbreviated pathway, or a private-label supply arrangement, depending on the product’s regulatory basis.
• Any patent analysis must distinguish active-ingredient patents, reference-product patents, formulation patents, and supplier-owned manufacturing patents.

What patents protect WAL-ITIN D and when does exclusivity end?

The basic loratadine and pseudoephedrine active ingredients are mature, off-patent compounds. The commercial product therefore has little practical protection from active-ingredient exclusivity.

Potentially relevant rights could include:

IP category	Likely relevance
Loratadine composition patents	Expired or commercially irrelevant for a current OTC product
Pseudoephedrine composition patents	Expired or commercially irrelevant
Extended-release formulation patents	Potentially relevant only if a specific formulation or process remains enforceable
Manufacturing-process patents	Could affect contract manufacturing or technology transfer
Packaging and trade dress	More relevant to private-label differentiation than drug exclusivity
Trademark rights	WAL-ITIN is a retail brand asset, not active-ingredient exclusivity

The main competitive barrier is formulation know-how and supply execution, not a broad patent moat. A competitor could develop a non-infringing extended-release formulation using different polymers, processing conditions, or coating architecture.

Are Paragraph IV challenges or patent litigation material risks?

Paragraph IV litigation is not the central risk for a mature private-label OTC product. The more probable risks are:

1. A supplier dispute involving a proprietary extended-release process.
2. A formulation patent assertion against a competing approved product.
3. Trade dress or trademark disputes involving store-brand packaging.
4. Contract-manufacturing disputes involving technical documentation or process ownership.
5. Regulatory action related to pseudoephedrine controls, labeling, or quality defects.

Any litigation review should search the specific manufacturer, product identifier, NDA or ANDA number, and current FDA listing. Product-level litigation cannot be inferred from the WAL-ITIN D brand name alone.

How does WAL-ITIN D compare with Claritin-D and competing products?

Attribute	WAL-ITIN D	Claritin-D	Other loratadine/pseudoephedrine products
Brand position	Walgreens private label	Originator or national brand	Generic or regional private label
Active ingredients	Loratadine plus pseudoephedrine	Loratadine plus pseudoephedrine	Usually equivalent strengths
Primary advantage	Lower retail price and Walgreens distribution	Brand recognition	Price and channel flexibility
Patent advantage	Limited	Mature product estate; formulation rights may vary	Usually limited
Excipient differentiation	Possible through dye-free, lactose-free, or smaller-tablet variants	Reference-product performance	Often cost-driven
Main barrier	Retail access and compliant supply	Brand demand and reference performance	Manufacturing and distribution

WAL-ITIN D competes on price, availability, and retailer trust. A premium excipient strategy is viable only if it creates a visible consumer benefit or reduces manufacturing risk.

What manufacturing and IP barriers affect commercial expansion?

The main manufacturing barriers are:

• Obtaining consistent pharmaceutical-grade pseudoephedrine sulfate.
• Managing loratadine segregation at low concentration.
• Achieving stable 24-hour release.
• Controlling dissolution under high humidity.
• Meeting pseudoephedrine inventory and transaction-control obligations.
• Maintaining continuity across contract manufacturers.
• Avoiding excipient changes that trigger regulatory or stability work.

The main IP barriers are narrower:

• A third party may hold rights to a particular extended-release matrix or coating system.
• A supplier may restrict use of a proprietary co-processed excipient.
• A contract manufacturer may own process improvements developed during scale-up.
• Packaging designs may create trade dress exposure.

A freedom-to-operate program should cover formulation patents, process patents, excipient supplier terms, packaging rights, and manufacturing-site ownership of development data.

What licensing deals and commercial partnerships are relevant?

The likely commercial model is private-label procurement rather than a public licensing transaction. Walgreens may source the product from a contract manufacturer or branded-generic supplier under a supply and quality agreement. Those agreements commonly address:

• Active-ingredient sourcing.
• Regulatory responsibility.
• Product release testing.
• Change-control procedures.
• Recall allocation.
• Patent indemnification.
• Minimum purchase volumes.
• Serialization and distribution requirements.
• Ownership of formulation and process improvements.

No standalone WAL-ITIN D revenue figure is generally disclosed. Revenue exposure should therefore be modeled through category sales, Walgreens distribution, product count, retail price, gross margin, and substitution rates against Claritin-D and other store-brand products.

What generic launch scenarios exist?

Three launch scenarios are commercially realistic:

Low-cost equivalent

The supplier uses a conventional extended-release tablet and matches the reference product’s performance at the lowest possible cost. This approach maximizes price competitiveness but creates limited brand differentiation.

Clean-label private label

The supplier removes colorants, replaces lactose, and uses a simplified excipient system. The product can support a modest premium if the packaging communicates the benefit clearly.

Premium delivery format

The supplier develops a smaller tablet, unit-dose blister, or improved swallowability profile. This creates stronger differentiation but has higher development, tooling, packaging, and regulatory costs.

The first scenario is most likely for mass retail. The second is the most practical innovation path. The third requires evidence that consumers will pay for the improved format.

Key Takeaways

• WAL-ITIN D is a mature OTC loratadine/pseudoephedrine extended-release product with limited active-ingredient patent protection.
• The core technical problem is controlled pseudoephedrine release combined with low-dose loratadine uniformity.
• A hydrophilic polymer matrix, robust blending controls, and conservative lubrication are central to product quality.
• Dye-free, lactose-free, smaller-tablet, and unit-dose presentations offer the clearest commercial opportunities.
• Pseudoephedrine controls create meaningful operational obligations for packaging, inventory, and retail execution.
• Orange Book and Paragraph IV strategies are generally less important than OTC regulatory compliance, formulation freedom to operate, and private-label supply agreements.
• The strongest competitive moat is reliable manufacturing and Walgreens distribution, not composition-of-matter exclusivity.

FAQs

Is WAL-ITIN D the same as Claritin-D?

It is generally positioned as an equivalent private-label product containing loratadine and pseudoephedrine, but the inactive ingredients, manufacturer, tablet design, and regulatory file can differ.

Can WAL-ITIN D be reformulated without a new patent risk?

Yes, but the reformulation must avoid third-party formulation and process claims. A new polymer, coating system, or manufacturing process should undergo a specific freedom-to-operate review.

Is lactose-free WAL-ITIN D commercially attractive?

It can be attractive as a private-label differentiation strategy, but the value depends on consumer demand, labeling clarity, incremental cost, and whether the replacement excipient changes dissolution or stability.

Does pseudoephedrine require special packaging?

Packaging does not replace statutory controls, but unit-dose or tamper-resistant packaging can improve inventory control, reduce diversion, and support retailer compliance.

Are biosimilar risks relevant to WAL-ITIN D?

No. WAL-ITIN D contains small-molecule active ingredients, not a biologic. Biosimilar competition is therefore not relevant; generic and private-label competition are the relevant market risks.

References

1. DailyMed. (n.d.). Loratadine and pseudoephedrine sulfate extended-release tablet labeling. U.S. National Library of Medicine.
2. Bayer Healthcare LLC. (n.d.). Claritin-D 24 hour drug facts label.
3. U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act requirements for pseudoephedrine and ephedrine products.
4. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.